Editas Medicine, Inc. announced that James C. Mullen, the Executive Chairman of the Board of Directors notified the Board that he does not intend to seek re-election as a director of the Company when his current term ends at the 2023 Annual Meeting of Stockholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.3 USD | -2.39% | +1.92% | -47.68% |
30/05 | Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating | MT |
14/05 | Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.68% | 436M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine, Inc. Announces That James C. Mullen, the Executive Chairman of the Board of Directors Will Not Stand for Re-Election as A Director